Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Reduction in Production Costs Poised to Impel Sales of Peptide Therapeutics, reports TMR

Transparency Market Research
Posted on: 14 Sep 16
Reduction in Production Costs Poised to Impel Sales of Peptide Therapeutics, reports TMR

The global peptide therapeutics market is highly fragmented, with the top three players representing nearly 52% of the overall market in 2013. The three leaders in this market are Teva Pharmaceutical Industries Ltd., Takeda Pharmaceuticals Co. Ltd., and Novo Nordisk. A large number of pharmaceutical companies are expected to enter the market in the coming years through acquisitions of small biotech players, predicts Transparency Market Research (TMR) in a new study. “Generic versions are a major threat to the branded drugs market. Their growth can be attributed to the fact that they are regarded as being equally effective while being lower in price,” says the author of the report. Moreover, high drug price and specific patient pools will drive consumer focus towards other biological and pharmaceutical drugs.

The global peptide therapeutics market was valued at US$19.98 bn in 2015 and is estimated to reach US$23.70 bn in 2020, expanding at a CAGR of 2.8% from 2014 to 2020. Geographically, North America was the most prominent segment in 2015. Due to high drug pricing and presence of a large patient pool, the region is estimated to maintain its leadership until 2020 with a valuation of US$9.74 bn. However, Asia Pacific is expected to grow at most promising CAGR of 3.6% during the same period.

Download free exclusive Brochure of this report:

Increasing Demand for Peptide Therapeutics in Cancer and Diabetes Treatment to Boost Sales

Technological advancements have encouraged manufacturers and suppliers to seek newer avenues for peptide manufacturing, which will improve production of longer and complex chains of peptides and reduce the production cost. The automation of instruments, with improvements in the purification process and reduction in the total waste generated, have triggered the growth of the global peptide therapeutics market.

Moreover, the growing concerns regarding side effects of chemotherapy and radiation have increased the demand for peptides in cancer treatment. The increasing demand for peptide drugs of the Glucagon-like peptide-1 (GLP-1) receptor agonist class from countries with a large pool of diabetic patients, especially India, has also given a significant boost to the global peptide therapeutics market. Furthermore, the growing number of peptide drugs in the pipeline indicate steady growth of this market.

Difficulty in Synthesis of Long Peptides to Challenge Peptide Therapeutics Manufactures

Synthesis and purification of long peptides is a major challenge for manufacturers. The rise in modifications and addition of more unnatural amino acids have further increased the complexity of synthesis. This makes the manufacturing of peptide difficult, thereby increasing the gap between demand and supply.

The lack of a harmonized and uniform set of guidelines to define the level of impurities permissible in peptide therapeutics has emerged as a challenge for peptide drug product manufacturers. Under such circumstances, the designing and manufacturing entail significant cost, thereby hampering the growth of the global peptide therapeutics market.

However, the increasing collaborations of biotech firms with large pharmaceuticals is anticipated to escalate the growth of the global peptide therapeutics market. Moreover, several manufacturers are working on the development of advanced technologies that will facilitate the manufacturing of accurate generic versions. This factor will provide immense growth opportunities in the forthcoming years.

View exclusive Global strategic Business report:

Cancer Emerges as Most Prominent Application Segment

By application, cancer was leading segment in 2015 and is expected to maintain its dominance in the peptide therapeutics market until 2020 with a valuation of US$7.96 bn. Due to the growing cases of respiratory issues, the respiratory segment will grow at an impressive CAGR of 87.8% from 2014 to 2020. On the basis of route of administration, parental will be the leading segment during the same period. Due to the growing awareness regarding benefits of oral route of administration to overcome the enzymatic degradation of peptides, the segment is expected to expand at a CAGR of 6.4% from 2014 to 2020.

The information presented in this review is based on a Transparency Market Research report, titled, ‘Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020’

The global peptide therapeutics market has been segmented as below:

Global Peptide Therapeutics Market, by Application


Zoladex (goserelin)

Velcade (bortezomib)

Lupron/ Enantone/ Eligard (leuprorelin)



Angiomax (bivalirudin)

Integrilin (eptifibatide)

Central Nervous System

Copaxone (glatiramer)

Metabolic Disorders

Victoza (liraglutide)

Byetta (exenatide)



Incivek (telaprevir)

Victrelis (boceprevir)

Hematological Disorders

Firazyr (icatibant)

Kalbitor (ecallantide)

Gastrointestinal Disorders

Gattex (teduglutide)

Linzess (linaclotide)


Respiratory Disorders


Other Applications

Global Peptide Therapeutics Market, by Route of Administration



Global Peptide Therapeutics Market, by Marketing Status



Global Peptide Therapeutics Market, by Geography

North America


Asia Pacific

Rest of the World

For more information:

Editor's Details

Ankit jain
Transparency Market Research

Last updated on: 14/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.